FIDELITY DISRUPTIVE MEDICINE ETF (FMED) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.10: the stock has moved about 10% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerFIDELITY DISRUPTIVE MEDICINE ETF (FMED) trades at $32.25. FIDELITY DISRUPTIVE MEDICINE ETF (FMED) focuses on investing in companies revolutionizing medical diagnostics, therapies, and services. The fund targets innovations like gene therapy, robotic surgery, and digital health platforms. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for FMED: FMED does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
FIDELITY DISRUPTIVE MEDICINE ETF (FMED) Financial Services Profile
FIDELITY DISRUPTIVE MEDICINE ETF (FMED) is a niche asset management fund targeting companies transforming the healthcare sector through innovative medical technologies and services. With a focus on disruptive medicine, FMED offers investors exposure to high-growth areas like gene therapy, robotic surgery, and digital health, distinguishing it from broader healthcare ETFs.
What Is the Investment Thesis for FMED?
FMED presents a focused investment opportunity within the high-growth area of disruptive medicine. The fund's concentration on companies transforming medical diagnostics, therapies, and services offers targeted exposure to innovative technologies like gene therapy, robotic surgery, and digital health. With a beta of 1.10, FMED exhibits slightly higher volatility compared to the broader market, potentially offering enhanced returns during periods of strong growth in the healthcare technology sector. Key catalysts include continued advancements in gene editing technologies, increasing adoption of robotic surgery, and the expansion of digital health platforms. These trends are expected to drive revenue growth for companies within FMED's portfolio. However, potential risks include regulatory hurdles, clinical trial failures, and competitive pressures from established healthcare companies. While FMED does not offer a dividend yield, its focus on capital appreciation through disruptive innovation makes it an interesting option for growth-oriented investors.
Based on FMP financials and quantitative analysis
FMED Key Highlights
Market Cap of $0.06B indicates a small-cap ETF focused on niche disruptive medicine companies.
- Beta of 1.10 suggests slightly higher volatility compared to the broader market.
- Focused investment strategy targeting companies transforming medical diagnostics, therapies, and services.
- Exposure to high-growth areas like gene therapy, robotic surgery, and digital health platforms.
- No dividend yield, indicating a focus on capital appreciation rather than income.
Who Are FMED's Competitors?
FMED is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AGGA EA Astoria Dynamic Core US Fixed Income ETF | $24.39 | -0.59% | $52.4M | — |
| CNXT VanEck ChiNext ETF | $44.99 | +1.19% | $99.0M | — |
| FDFF FIDELITY DISRUPTIVE FINANCE ETF | $34.97 | +1.76% | $40.6M | — |
| JANT AllianzIM U.S. Equity Buffer10 Jan ETF | $45.59 | +0.38% | $64.6M | — |
| PRXG Praxis Impact Large Cap Growth ETF | $41.58 | +0.74% | $92.2M | — |
| BLK BlackRock, Inc. | $1066.45 | +0.64% | $165B | 51 5-pillar |
| BX Blackstone Inc. | $111.64 | -0.09% | $136B | 68 5-pillar |
| APOS Apollo Global Management, Inc. | $25.59 | 0.00% | $74.8B | 56 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FMED's Key Strengths?
Focus on high-growth disruptive medicine sector.
- Potential for significant capital appreciation.
- Diversification within the disruptive medicine space.
- Expertise in identifying innovative healthcare companies.
What Are FMED's Weaknesses?
Small market capitalization ($0.06B).
- Higher volatility compared to broader market (beta of 1.10).
- Concentrated investment strategy.
- Dependence on the success of disruptive technologies.
What Are the Key Risks for FMED?
Regulatory hurdles and clinical trial failures delaying commercialization of new therapies.
- Competitive pressures from established healthcare companies limiting market share.
- Technological obsolescence rendering existing technologies obsolete.
- Economic downturn impacting healthcare spending and investment.
- Ethical concerns surrounding gene editing technologies.
What Are FMED's Competitive Advantages?
- Focus on a specific niche within the healthcare sector (disruptive medicine).
- Expertise in identifying and evaluating innovative healthcare companies.
- Potential for high growth due to exposure to disruptive technologies.
- Diversification within the disruptive medicine space.
What Does FMED Do?
FIDELITY DISRUPTIVE MEDICINE ETF (FMED) is designed to provide investors with targeted exposure to companies at the forefront of medical innovation. The fund invests in businesses that are actively transforming medical diagnostics, therapies, and services, encompassing a range of cutting-edge fields such as gene therapy, robotic surgery, and digital health platforms. FMED aims to capture the growth potential of companies that are disrupting traditional healthcare models through technological advancements. The ETF's investment strategy focuses on identifying companies that are pioneering new approaches to healthcare delivery and treatment. This includes companies developing novel diagnostic tools, advanced surgical techniques, and innovative digital health solutions. By concentrating on disruptive technologies, FMED seeks to outperform broader healthcare indices and provide investors with access to high-growth opportunities within the healthcare sector. FMED's portfolio construction involves a rigorous selection process to identify companies with strong growth prospects and disruptive potential. The fund's managers conduct in-depth research to assess the technological capabilities, market opportunities, and competitive positioning of potential investments. This process helps to ensure that FMED's portfolio is composed of companies that are well-positioned to capitalize on the evolving healthcare landscape. As of 2026, FMED continues to focus on identifying and investing in companies that are shaping the future of medicine.
What Products and Services Does FMED Offer?
- Invests in companies transforming medical diagnostics.
- Targets companies developing innovative therapies.
- Focuses on advancements in gene therapy.
- Includes companies involved in robotic surgery.
- Invests in digital health platforms.
- Seeks to capture growth potential in disruptive medicine.
How Does FMED Make Money?
- Invests in publicly traded companies.
- Generates revenue through management fees.
- Aims to provide capital appreciation for investors.
- Rebalances portfolio to maintain focus on disruptive medicine.
What Industry Does FMED Operate In?
The asset management industry is undergoing significant transformation, driven by technological innovation, changing investor preferences, and increasing regulatory scrutiny. ETFs like FMED are gaining popularity as investors seek targeted exposure to specific sectors and investment themes. The healthcare sector, in particular, is experiencing rapid innovation, with disruptive technologies like gene therapy, robotic surgery, and digital health platforms transforming traditional healthcare models. FMED is positioned to capitalize on these trends by investing in companies that are at the forefront of medical innovation. Competitors include AGGA, CNXT, FDFF, JANT, and PRXG, each offering different approaches to healthcare investing.
Who Are FMED's Key Customers?
- Retail investors seeking exposure to healthcare innovation.
- Institutional investors looking for targeted healthcare investments.
- Financial advisors seeking diversified investment options.
- High-net-worth individuals interested in disruptive technologies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 41 snapshots
| 2026-08-23 | 44 |
| 2026-08-31 | 44 |
| 2026-09-08 | 44 |
| 2026-09-16 | 44 |
| 2026-09-24 | 44 |
| 2026-10-04 | 44 |
What changed?
The score has stayed at 44.
Over the same 30 days the stock moved -0.7%.
FMED Financials
Bull Case vs Bear Case
Bull Case
- Focus on high-growth disruptive medicine sector.
- Potential for significant capital appreciation.
- Diversification within the disruptive medicine space.
- Expertise in identifying innovative healthcare companies.
Bear Case
- Small market capitalization ($0.06B).
- Higher volatility compared to broader market (beta of 1.10).
- Concentrated investment strategy.
- Dependence on the success of disruptive technologies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
FMED Latest News
No recent news available for FMED.
FMED Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for FMED.
Price Targets
Wall Street price target analysis for FMED.
FMED MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for FMED; grades run from A+ (80-100) to F (below 30).
Common Questions About FMED (Financials)
What do analysts say about FMED stock?
Generally, ETFs focused on disruptive technologies may be viewed as higher-risk, higher-reward investments. Key valuation metrics would include the growth rates of the underlying companies and the overall market sentiment towards innovative healthcare solutions.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- The disruptive medicine sector is subject to rapid technological change and regulatory uncertainty.